|
FY2025
12 months to Dec 31, 2025
|
FY2024
12 months to Dec 31, 2024
|
FY2023
12 months to Dec 31, 2023
|
|
|---|---|---|---|
| Gross Sales | |||
| Cost of sales | |||
| Gross Margin | |||
| Operating Expenses: | |||
| Professional fees | |||
| General and administrative | |||
| Consulting | |||
| Total operating expenses | |||
| Operating loss from continuing operations | |||
| Change in fair value of derivatives | |||
| Change in fair value of derivatives | |||
| Change in fair value of contingent liabilities | |||
| Loss on sale of asset | |||
| Loss on issuance of derivative | |||
| Gain on extinguishment of debt | |||
| Loss on impairment of assets | |||
| Unrealized loss on investment in WTXR | |||
| Gain on extinguishment of derivative liability | |||
| Amortization of intangible assets | |||
| Interest income | |||
| Interest expense | |||
| Total other expense, net | |||
| Loss from continuing operations | |||
| Discontinued Operations: | |||
| Loss from discontinued operations | |||
| Loss from shutdown of Axenic | |||
| Total Discontinued Operations | |||
| Net loss before income taxes | |||
| Provision for income taxes | |||
| Net Loss | |||
| Loss attributable to noncontrolling interest | |||
| Common stockholders | |||
| Net loss attributable to common stockholders | |||
| Loss per share, basic | |||
| Loss per share, diluted | |||
| Weighted average shares outstanding, basic | |||
| Weighted average shares outstanding, diluted |
Loading...
